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Di(2-ethylhexyl) Adipate: Condensation
of the Carcinogenesis Bioassay
Technical Report*
Di(2-ethylhexyl) adipate[bis(2-ethylhexyl)adipate,
DEHA, octyl adipate, dioctyl adipate, DOA, CAS
No. 103-23-1], a plasticizer added to vinyl plastics
to give low temperature flexibility, is dispersed
(not bound) in the polymer chain matrix. Approved
by the U.S. Food and Drug Administration for use
in plastics that may contact nonfatty, nonalcoholic
foods (not to exceed 24% by weight of the plastic
polymer), DEHA has wide use in vinyl packaging
ifim for refrigerated and frozen food products.
Other products containing DEHA include electric
wire insulation, garden hoses, vinyl coated fabrics
for automotive and upholstery use, synthetic rub-
ber, base oils for hydraulic fluids, and, among
others, polyvinyltubingforhemodialysis. Forthese
uses 44 million pounds were produced in 1978.
DEHA was selected as a representative of the
adipate class ofplasticizers, because it is structur-
ally related to di(2-ethylhexyl) phthalate, because
human exposure is widespread, and because no
carcinogenesis studies had been done. Testing was
initiated by the Carcinogenesis Testing Program,
National Cancer Institute (now part ofthe National
InstituteofEnvironmentalHealthSciences/National
Toxicology Program).
Methods
Male and female inbred Fischer344rats andmale
and female hybrid B6C3F1 mice, obtained from the
Frederick Cancer Research Center, were used in
this bioassay. For 103 consecutive weeks all groups
received powdered Wayne Lab Blox. Treated groups
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were fed this diet containing 12,000 ppm or 25,000
ppm di(2-ethylhexyl) adipate (> 98% pure).
This carcinogenesis bioassay was conducted
between April 1977 and May 1979 at EG&G Mason
Research Institute under a subcontract to Tracor
Jitco (prime contractor for the testing program).
All animals that died during the study or that
were killed at the end ofthe exposure period were
subjected to a gross necropsy and a complete
histopathological examination. Statistical analyses
comparing survival and numbers of animals with
specific site tumors were done with trend tests and
pairwise comparisons (1-4). The study design con-
formed to the NCI Guidelines for carcinogen bioas-
say (5).
Results
Mean body weights ofhigh dose male and female
rats and treated male and female mice were lower
than the corresponding controls. Survival was com-
parable among all groups of mice and male rats;
survival in the female control rats was reduced
relative to the treated groups (29/50 control, 39/50
low dose, 44/50 high dose).
The number of DEHA-treated rats with specific
site tumors did not differ significantly from those
found in controls. Table 1 lists those primary
tumors occuring in at least three animals of any
one group.
Liver tumors occurred with significantly higher
frequencies in treated male and female mice than in
controls (Table 2). Other specific site tumors were
not significantly increased in treated mice when
compared to controls (Table 3).
Discussion
In male rats the positive dose-related trend (p =
0.010) and the statistically significant (p<0.05)
increase in interstitial cell testicular tumors in the206 CONDENSATION
Table 1. Primary tumors in male and female F344 rats fed diets containing di(2-ethylhexyl) adipate.
Male Female
Tumor Control 12,000 ppm 25,000 ppm Control 12,000 ppm 25,000 ppm
Adrenal cortical adenoma 1/48 1/50 0/50 3/50 0/50 0/48
Adrenal pheochromocytoma 6/48 3/50 1/50 1/50 2/50 3/48
Hepatocellular carcinoma 0/49 1/50 2/50 0/49 1/50 0/50
Hepatocellular neoplastic nodule 2/49 1/50 0/50 0/49 2/50 1/50
Leukemia 9/49 11/50 8/50 12/50 5/50 10/50
Mammary gland 1/49 2/50 0/50 14/50 6/50 3/50
Mesothelioma 1/49 1/50 3/50 0/50 0/50 0/50
Pituitary adenoma or carcinoma 4/44 3/47 3/44 21/47 25/48 18/49
Preputial gland carcinoma 1/49 4/50 1/50a - - _
Skin squamous cell papilloma 1/49 4/50 1/50 0/50 0/50 0/50
Subcutaneous fibroma 4/49 1/50b 2/50 0/50b 1/50 0/50C
Testicular interstitial cell 43/49 47/50 49/49 - - -
Thyroid C-cell carcinoma or adenoma 3/49 4/49 1/46 4/50 0/50 3/47
Uterine endometrial stromal polyp - - - 11/50 10/50 13/50
bOne other animal had a subcutaneous febrosarcoma.
COne female had a subcutaneous fibroadenoma.
Table 2. Primary liver tumor increases in male and female B6C3F, mice fed diets containing di(2-ethylhexyl) adipate.
Males Females
Hepatocellular tumor Control 12,000 ppm 25,000 ppm Control 12,000 ppm 25,000 ppm
Carcinomaa 7/50 12/49 12/49b 1/50 14/50c 12/49d
Adenomae 6/50 8/49 15/49f 2/50 5/50 6/49
Carcinoma or adenomag 13/50 20/49 27/49d 3/50 19/50c 18/49C
aSignificant dose-related trend for females (p < 0.005).
bOne other male had a neoplasm, NOS (not otherwise specified).
CSignificantly greater than controls (p < 0.001).
dSignificantly greater than controls (p < 0.005).
eSignificant dose-related trend for males (p < 0.05).
fSignificantly greater than controls (p < 0.05).
gSignificant dose-related trend for males and females (p <0'.005).
Table 3. Primary tumors in male and female B6C3F1 mice fed diets containing di(2-ethylhexyl) adipate.
Males Females
Tumor Control 12,000 ppm 25,000 ppm Control 12,000 ppm 25,000 ppm
Circulatory system: angiosarcoma, 2/50 2/50 1/50 3/50 3/50 3/49
hemangioma, hemangiosarcoma
Lymphoma 16/50 7/50 6/49 23/50 14/50 7/49
Lung alveolar/bronchiolar adenoma 8/50 9/49 3/49 5/49a 1/49 3/48
Pituitary adenoma 0/40 0/31 0/36 8/39 6/37 0/39
Subcutaneous fibroma or fibrosarcoma 5/50 3/50 0/49 2/50b 0/50 2/50
or sarcoma, NOS
aOne other female rat had an alveolar/bronchiolar carcinoma.
bOne other female rat had a neoplasm, NOS (not otherwise specified).
high dose group were not considered compound
related since most (> 80%) aging F344 male rats
have this lesion.
Significant negative trends were obtained for
male rats with adrenal gland pheochromocytomas
(p < 0.05) and for female rats with adrenal cortical
adenomas (p < 0.05) and with mammary gland
fibroadenomas (p = 0.001).
Hepatocellularcarcinomas wereincreasedinboth
low and high dose female mice; hepatocellular
adenomas or carcinomas combined occurred in high
dose mice ofeither sex and in low dose female mice
atincidencesthatweredoserelatedand significantly
higher than those in the controls. The time to
observation of hepatocellular adenomas or carcino-
mas in the dosed female mice, but not in dosed maleDI(2-ETHYLHEXL) ADIPATE 207
mice, was significantly shorter than the time to
observationofthesetumorsinthecontrols. Because
the increase in livertumors inmales reflects onlyan
increase in adenomas for the high dose group and
because the time to observation oftumors in dosed
groups as compared with the control group was not
significantlydifferent, theassociation oflivertumors
in the males with administration ofdi(2-ethylhexyl)
adipate is not considered conclusive.
Hepatocellular adenoma compressed the adja-
cent liver tissue. Cells in the adenoma were large.
Cytoplasm ofthe cells was acidophilic or vacuolated
and nuclei were hyperchromatic. Hepatocellular
carcinoma involved a part or an entire lobe of the
liver. The lobular architecture was distorted and
cell plates were two or more cells thick, forming
trabeculae. Cellular pleomorphism was apparent.
The nuclei had coarse chromatin, and the nucleoli
were prominent. Both normal and abnormal mitotic
figures were numerous. Areas of necrosis and
mineralization were common in the large tumors.
Hepatocellular carcinoma metastasized to the
lung in 14 male mice (control, 5; low dose, 4; high
dose, 5) and in 11 female mice (low dose, 6; high
dose, 5). In all cases, the primary livertumors were
of the trabecular type. The other sites of metasta-
ses were the kidney, adrenal, and lymph nodes in
dosed female mice.
The historical incidence of liver tumors in male
B6C3F1 mice atthis laboratoryis: adenomas, 35/398
(9%, range 0-16%); carcinomas, 86/398 (22%, range
14-30%); combined tumors, 116/398 (29%, range
18-36%). The historical incidence of tumors in
female B6C3F1 mice at this laboratory is: adeno-
mas, 18/397 (5%, range 0-18%); carcinomas, 14/397
(4%, range 0-8%); combined tumors, 31/397 (8%,
range 2-20%).
Negative trends were calculated for male (p =
0.010) and for female (p = 0.001) mice with
lymphomas; the number of mice in each treated
group with lymphoma was significantly less (p <
0.05) thanthecorrespondingcontrols. Thisinterest-
ingphenomenon ofdecreasesinleukemias/lymphomas
concomitant with increases in hepatocellular neo-
plasms is receiving considerable research attention
from the National Toxicology Program (6).
Di(2-ethylhexyl) adipate was not mutagenic for
Salmonella typhimurium TA 1535, TA 1537, TA
1538, TA 98, and TA 100, with and without
activation, or for Saccharomyces cerevisiae (7).
Di(2-ethylhexyl) adipate is teratogenic for Sprague-
Dawley rats (8) and causes dominant lethal muta-
tions in ICR mice (9).
In conclusion and under the conditions of this
bioassay, di(2-ethylhexyl) adipate was not carcino-
genic for F344 rats of either sex. Di(2-ethylhexyl)
adipate was carcinogenic for female B6C3F1 mice
causing increased numbers of female mice with
hepatocellular carcinomas, and was probably carci-
nogenic for male B6C3F1 mice, causing increased
numbers of male mice with hepatocellular adeno-
mas as well as inducing increased numbers ofmale
mice with combined hepatocellular adenomas or
carcinomas (10).
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